/THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES/
TORONTO, Sept. 29 /CNW/ - Biosign Technologies Inc. (CNSX: BIO) today announced a long-term commercial agreement with NovaMed Diagnostics Inc. Under the terms of the agreement, Biosign will provide devices and services for blood pressure and cardiovascular assessment, with priority delivery of new releases as they become available.
"This agreement marks our entry in the lucrative medical diagnostics market," said John Anders, Biosign's VP Business Development and Sales. "UFIT(R) will enable NovaMed to reduce the time, cost, and inconvenience of selected cardiac evaluations while significantly improving data quality."
NovaMed, being the leader in ambulatory event loop cardiac monitoring in Ontario, offers a full complement of non-invasive cardiac services through state of the art technology. The company provides cardiovascular evaluation and risk assessments for thousands of patients per year. NovaMed also serves the growing need for self-monitoring, focusing on risk factor assessment, preventative care, and wellness management. By utilizing a multifaceted approach of best care practices, clinical pathways, "smart" technology and information systems, NovaMed is well positioned to address the rapidly rising rate of chronic disease.
"Biosign's UFIT(R) system is well-suited for the fast growing diagnostic market and will vastly improve patient compliance as well as our clinician's needs." said Anna Del Duca, President of NovaMed Diagnostics Inc. "In ambulatory blood pressure alone, it effectively replaces systems that are costly, uncomfortable, and which fall short of providing sufficient relevant data for the proper evaluation and subsequent treatment of hypertension."
Immediate delivery consists of Biosign's blood pressure monitors (UFIT(R) TEN-10) with server controls for quality assurance, including automatic scheduling, result verification, tracking, charting and trending. NovaMed shall initially deploy the UFIT(R) TEN-10 for its recently announced use in ambulatory blood pressure monitoring (see Biosign News dated September 25, 2009), as well as for use in the NovaMed clinic.
With its advanced diagnostic capability, UFIT(R) significantly reduces the number of blood pressure readings thus increasing patient adherence. UFIT(R) redefines the method by which medical monitoring systems are used in the health care arena by optimizing data collection and empowering patients while providing much needed cost reduction relief to the health care system.
About NovaMed Diagnostics Inc.
NovaMed is a leading provider throughout Southwestern Ontario of cardiovascular assessment, having pioneered the implementation of loop monitoring for clinical and hospital-based cardiac investigation. Loop monitoring is recognized as an industry standard for effective arrhythmia detection amongst cardiologists and electro physiologists. The on-site monitoring centre provides immediate diagnostic recognition and notification of electrocardiogram abnormalities. NovaMed's comprehensive team of healthcare providers and community partners strive to optimize risk assessment and wellness management programs in both primary and secondary prevention.
About Biosign Technologies Inc.
Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines universal measurement, remote monitoring, and rapid knowledge formation to support health care across global markets. The UFIT(R) technology powers quality data collection and analytics for clinical diagnostics, disease evaluation & management, remote patient monitoring, and self-care. For more information on Biosign please visit http://www.biosign.com.
This press release contains forward looking statements. Forward looking statements are not based on historical facts, but rather on current expectations, Company assumptions and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Company assumptions and risk factors are listed from time to time in Biosign's reports, public disclosure documents including Management's Discussion and Analysis, Management Information Circular, and in other filings with stock exchanges and securities regulatory authorities in Canada. You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. While Biosign may elect to, Biosign is under no obligation and does not undertake to update this information at any particular time. This press release was prepared by management from information available to the date of this release.
The CNSX has neither approved nor disapproved the contents of this press
SOURCE Biosign Technologies Inc.
For further information: For further information: Radu Leca, President, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 234, Email: firstname.lastname@example.org; Anna Del Duca, President, NovaMed Diagnostics Inc., Phone: (519) 987-0611, Email: email@example.com